Illuccix® Reimbursement Milestone and Launch Updates: P

MELBOURNE, Australia and INDIANAPOLIS, May 30, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on the U.S. and Australian launch and reimbursement status for its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium (68Ga) gozetotide). U.S. Launch Update: Full reimbursement in the U.S. to be effective from July 1...

Related Keywords

Australia , Japan , Melbourne , Victoria , United States , Canada , Switzerland , Belgium , Australian , American , Kyahn Williamson , Davidn Cade , Telix Asia Pacific , Christian Behrenbruch , Telix Pharmaceuticals , Linkedin , Veterans Affairs , Drug Administration , Australian Securities Exchange , Global Medical Solutions Australia , Prnewswire Telix Pharmaceuticals Limited , Australian Therapeutic Goods Administration , Us Centers For Medicare , Corporate Communications , United Pharmacy Partners Inc , Cardinal Health , Company Appendix , Medicaid Services , Pharmaceuticals Limited , Transitional Pass Through Payment Status , Healthcare Common Procedure Coding System , United Pharmacy Partners , Federal Supply Service , Activities Report , Medicare Benefits Schedule , Asia Pacific , Molecularly Targeted Radiation , Safety Information , Managing Director , Group Chief Executive , Telix Pharmaceuticals Limited ,